Britannia gets North American rights to Apokyn from Ipsen; USWorldMeds will Commercialize in the US
Executive Summary
Orphan disease drug developer Britannia Pharmaceuticals Ltd. has licensed rights in North America to develop and market Ipsen’s Apokyn (apomorphine), an approved therapy for acute intermittent treatment of hypomobility “off” episodes that can accompany advanced Parkinson’s disease.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice